Redirecting T cells to treat solid pediatric cancers
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
http://link.springer.com/content/pdf/10.1007/s10555-019-09821-5.pdf
Reference155 articles.
1. Rossig, C., Juergens, H., Schrappe, M., Moericke, A., Henze, G., von Stackelberg, A., et al. (2013). Effective childhood cancer treatment: the impact of large scale clinical trials in Germany and Austria. Pediatric Blood & Cancer, 60(10), 1574–1581.
2. Stahl, M., Ranft, A., Paulussen, M., Bolling, T., Vieth, V., Bielack, S., et al. (2011). Risk of recurrence and survival after relapse in patients with Ewing sarcoma. Pediatric Blood & Cancer, 57(4), 549–553.
3. Bielack, S. S., Kempf-Bielack, B., Branscheid, D., Carrle, D., Friedel, G., Helmke, K., et al. (2009). Second and subsequent recurrences of osteosarcoma: presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoma study group patients. Journal of Clinical Oncology, 27(4), 557–565.
4. Rossig, C., Juergens, H., & Berdel, W. E. (2011). New targets and targeted drugs for the treatment of cancer: an outlook to pediatric oncology. Pediatric Hematology and Oncology, 28(7), 539–555.
5. Doebele, R. C., Davis, L. E., Vaishnavi, A., Le, A. T., Estrada-Bernal, A., Keysar, S., et al. (2015). An oncogenic NTRK fusion in a patient with soft-tissue sarcoma with response to the tropomyosin-related kinase inhibitor LOXO-101. Cancer Discovery, 5(10), 1049–1057.
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers;Clinical Cancer Research;2024-04-09
2. Navigating Tumour Microenvironment and Wnt Signalling Crosstalk: Implications for Advanced Cancer Therapeutics;Cancers;2023-12-14
3. CAR T cells as micropharmacies against solid cancers: Combining effector T-cell mediated cell death with vascular targeting in a one-step engineering process;Cancer Gene Therapy;2023-06-30
4. Avelumab in paediatric patients with refractory or relapsed solid tumours: dose-escalation results from an open-label, single-arm, phase 1/2 trial;Cancer Immunology, Immunotherapy;2022-03-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3